Laboratorio Cosmoral registers EUR 25.4m revenue in 2023, up 28% over 2022
Laboratorio Cosmoral registra una facturación de EUR 25,4m en 2023, un 28% más que en 2022
Intel ID : 395561
|
||||
| Intel ID | 395561 | |
| Value | EUR 25,40m | |
| Native Currency | Euro (EUR) | |
|
Financial Data - Laboratorio Cosmoral
(31 Dec 2023) |
Revenue: EUR 25,68m EBITDA: EUR 1,92m Net Debt: EUR 0,24m People: 76 |
|
| Date |
 |
|
| Country | |
|
| Geography |  |
|
| Subsector (Old TTR Sectors) |
|
|
| Primary Subsector (TTRSC) |
30.01.03 Pharmaceutical R&D, Manufacturing & Distribution (Primary) 30 Healthcare / 30.01 Biotechnology & Pharmaceuticals |
|
| Secondary Subsectors (TTRSC) |
30.01.04 Specialty Pharmaceuticals 30 Healthcare / 30.01 Biotechnology & Pharmaceuticals 30.01.01 Biopharmaceuticals 30 Healthcare / 30.01 Biotechnology & Pharmaceuticals |
|
| Type |
|
|
| Intel Grade |
|
|
| Source |
|
|
| Tags | |
Target
| Name |
|
||
| Subsector (Old TTR Sectors) |
|
||
| Primary Sector (TTRSC) |
30.01.03 Pharmaceutical R&D, Manufacturing & Distribution 30 Healthcare / 30.01 Biotechnology & Pharmaceuticals |
||
| Secondary Sectors (TTRSC) |
30.01.01 Biopharmaceuticals 30 Healthcare / 30.01 Biotechnology & Pharmaceuticals 30.01.04 Specialty Pharmaceuticals 30 Healthcare / 30.01 Biotechnology & Pharmaceuticals |
||
| Country |
|
||
| Description |
|
Legend:
Verified: Confirmed as a party to an active or possible transaction.
Potential: Unconfirmed as a party to an active or possible transaction.
Retained: Confirmed as “Retained” with a general or specific mandate.
Prospect: Advisory “Prospect” in discussions with or pitching services to possible client.
Transactional data is continuously updated by the research team and therefore is subject to change.